In the glare of an intense gene therapy spotlight, bluebird continues to tout each small step forward for its pioneering LentiGlobin
As one of the pioneers in the new wave of gene therapy developers, bluebird bio $blue has spent considerable time providing incremental evidence that it can step up results for LentiGlobin, improving the manufacturing process and beefing up positive outcomes for a therapy that’s had its problems along the way.
Today, the research team has two new updates to offer on a handful of patients afflicted by an inability to produce sufficient quantities of healthy hemoglobin, couched in the relentlessly optimistic terms that has helped CEO Nick Leschly build their market cap to close to $10 billion. Preparing for an update this weekend at the 23rd Congress of the European Hematology Association, they need to impress analysts in the lead-up to a crucial marketing application.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.